Acthar is FDA-approved to treat an exacerbation or as maintenance therapy in

Systemic Lupus Erythematosus (SLE)1

Lupus Overview Image

*While the exact mechanism of action of Acthar is unknown, further investigation is being conducted. This information is based on nonclinical data and the relationship to clinical benefit is unknown.

Mallinckrodt is committed to supporting patients.

Services are available to help patients gain access to and get started on Acthar. The Acthar Hub assists patients with:

  • Determining insurance coverage
  • Obtaining co-pay assistance, as needed
  • Scheduling Acthar injection training
  • Coordinating with the Specialty Pharmacy

IMPORTANT SAFETY INFORMATION

SEE More

Contraindications

  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
  • Acthar is contraindicated where congenital infections are suspected in infants
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins

INDICATIONS

SEE More

H.P. Acthar® Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for:

  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
  • The treatment of symptomatic sarcoidosis
  • Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)